Is AIM ImmunoTech Inc (AIM) a Winner in the Biotechnology Industry? – InvestorsObserver

A rating of 12 puts AIM ImmunoTech Inc (AIM) near the bottom of the Biotechnology industry according to InvestorsObserver. AIM ImmunoTech Inc's score of 12 means it scores higher than 12% of stocks in the industry. AIM ImmunoTech Inc also received an overall rating of 20, putting it above 20% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 20 would rank higher than 20 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

AIM ImmunoTech Inc (AIM) stock is lower by -2.91% while the S&P 500 has gained 0.39% as of 10:43 AM on Wednesday, Dec 23. AIM is down -$0.06 from the previous closing price of $2.06 on volume of 958,792 shares. Over the past year the S&P 500 has gained 14.83% while AIM has gained 308.16%. AIM lost -$0.44 per share the over the last 12 months.

Click Here to get the full Stock Score Report on AIM ImmunoTech Inc (AIM) Stock.

Read more:
Is AIM ImmunoTech Inc (AIM) a Winner in the Biotechnology Industry? - InvestorsObserver